Saturday 17 October 2026
Export QURE’s income statement to Excel — free account
uniQure N.V.
QURE Healthcare Biotechnology
uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.
21.72
0.80
−3.55%
Follow QURE
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
216.85 | 85.48 | 56.70 | 163.41 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(208.28) | (17.74) | (26.82) | (106.77) | |
P/B ratio |
14.93 | 6.92 | 6.87 | 9.42 | |
Price to Tangible BV |
26.42 | 13.66 | 18.81 | 12.85 | |
EV/Sales |
176.59 | 50.40 | 27.50 | 123.14 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(18.15) | (4.56) | (2.89) | (14.30) | |
EV/FCF |
(17.85) | (4.49) | (2.85) | (14.05) | |
Quick Ratio |
6.94 | 9.99 | 9.97 | 9.79 | |
Current Ratio |
7.12 | 10.43 | 10.40 | 10.01 | |
Net Debt/EBITDA |
13.55 | 11.90 | 12.55 | 16.07 | |
Debt/Assets |
5.84% | 6.02% | 6.41% | 5.09% | |
Debt/Equity |
0.23 | 0.25 | 0.33 | 0.15 | |
Asset Turnover |
0.02 | 0.02 | 0.03 | 0.02 | |
Operating CF/Net income |
0.20 | 2.09 | 0.71 | 0.35 | |
Capex/Depreciation |
0.02 | (0.04) | (0.05) | (0.10) | |
Interest Coverage |
(3.05) | (3.51) | (3.26) | (3.63) | |
Research and Development Expense of Revenue |
928.56% | 624.71% | 819.09% | 581.48% | |
Selling, General and Administrative Expense of Revenue |
525.21% | 388.11% | 563.39% | 297.33% | |
Intangible Assets out of Total Assets |
0.11 | 0.12 | 0.12 | 0.09 | |
Share Based Compensation of Revenue |
95.16% | 83.75% | 142.90% | 85.88% | |
Graham Net Nets |
0.02 | 0.02 | (0.01) | 0.06 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(7.52%) | (14.42%) | (21.28%) | (8.71%) | |
Free Cash Flow Yield |
(4.56%) | (13.13%) | (17.04%) | (5.36%) | |
Revenue per Share |
0.06 | 0.10 | 0.06 | 0.09 | |
Operating CF per Share |
(0.28) | (1.35) | (0.61) | (0.43) | |
Capex per Share |
0.00 | 0.00 | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.28) | (1.35) | (0.61) | (0.44) | |
Cash per Share |
11.86 | 10.83 | 9.35 | 12.23 | |
Shareholders Equity per Share |
3.91 | 3.46 | 2.38 | 4.89 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.91 | 3.46 | 2.38 | 4.89 | |
Free Cash Flow |
(16.33) | (77.69) | (38.38) | (29.05) | |
Working Capital |
615.56 | 593.07 | 556.55 | 750.92 | |
Capital Expenditures |
0.07 | (0.12) | (0.14) | (0.47) | |
Net Current Asset Value |
56.56 | 29.98 | (13.62) | 173.22 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.02) | 0.02 | 0.04 | 0.08 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
4.60 | 5.87 | 3.04 | 5.69 | |
Average Payables |
5.83 | 6.20 | 4.83 | 5.26 | |
Average Assets |
767.09 | 690.72 | 692.05 | 785.00 | |
Average Common Equity |
142.28 | 96.07 | 91.51 | 160.02 |
Columns are period end dates